BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dunbar H, Weiss DJ, Rolandsson Enes S, Laffey JG, English K. The Inflammatory Lung Microenvironment; a Key Mediator in MSC Licensing. Cells 2021;10:2982. [PMID: 34831203 DOI: 10.3390/cells10112982] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Cao C, Zhang L, Liu F, Shen J. Therapeutic Benefits of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome: Potential Mechanisms and Challenges. J Inflamm Res 2022;15:5235-46. [PMID: 36120184 DOI: 10.2147/JIR.S372046] [Reference Citation Analysis]
2 Weiss DJ, Filiano A, Galipeau J, Khoury M, Krampera M, Lalu M, Blanc KL, Nolta J, Phinney DG, Rocco PR, Shi Y, Tarte K, Viswanathan S, Martin I. An ISCT MSC Committee Editorial on overcoming limitations in clinical trials of mesenchymal stromal cell therapy for COVID-19: Time for a global registry. Cytotherapy 2022. [DOI: 10.1016/j.jcyt.2022.07.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Mönch D, Reinders MEJ, Dahlke MH, Hoogduijn MJ. How to Make Sense out of 75,000 Mesenchymal Stromal Cell Publications? Cells 2022;11:1419. [DOI: 10.3390/cells11091419] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]